Document ID: chunk:federal_register_of_legislation:F2024L01325:front:0:p1
Version: federal_register_of_legislation:F2024L01325
Segment Type: other
Provision Reference: 
Character Range: 0–3859

Statement of Principles
concerning
MYELODYSPLASTIC NEOPLASM (SYNDROME)
(Reasonable Hypothesis)
(No. 76 of 2024)
The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.

Dated    18 October 2024.

Professor Terence Campbell AM
Chairperson
by and on behalf of
The Repatriation Medical Authority

Contents
1 Name
2 Commencement
3 Authority
4 Repeal
5 Application
6 Definitions
7 Kind of injury, disease or death to which this Statement of Principles relates
8 Basis for determining the factors
9 Factors that must exist
10 Relationship to service
11 Factors referring to an injury or disease covered by another Statement of Principles
Schedule 1 - Dictionary
1 Definitions

 1.                Name
This is the Statement of Principles concerning myelodysplastic neoplasm (syndrome) (Reasonable Hypothesis) (No. 76 of 2024).
 1.                Commencement
              This instrument commences on 19 November 2024.
 1.                Authority
This instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.
 1.                Repeal
The Statement of Principles concerning myelodysplastic syndrome (No. 73 of 2015) (Federal Register of Legislation No. F2015L00905) made under subsections 196B(2) and (8) of the VEA is repealed.
 1.                Application
This instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.
 1.                Definitions
The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.
 1.                Kind of injury, disease or death to which this Statement of Principles relates
         1.           This Statement of Principles is about myelodysplastic neoplasm (syndrome) and death from myelodysplastic neoplasm (syndrome).
Meaning of myelodysplastic neoplasm (syndrome)
 1.           For the purposes of this Statement of Principles, myelodysplastic neoplasm (syndrome):
         1.           means a clonal haematopoietic stem cell neoplasm characterised by morphologic dysplasia ≥10% in at least one cell line of erythroid, granulocyte, or megakaryocyte lines; persistent cytopaenia; progressively ineffective haematopoiesis; and increased risk of acute myeloid leukaemia; and
         2.           includes:
                 1.             morphologically defined myelodysplastic neoplasm including myelodysplastic neoplasm with low blasts; hypoplastic myelodysplastic neoplasm; and myelodysplastic neoplasm with increased blasts; and
                 2.          myelodysplastic neoplasms with defined genetic abnormalities including myelodysplastic neoplasm with low blasts and 5q deletion; myelodysplastic neoplasm with low blasts and SF3B1 mutation; myelodysplastic neoplasm with biallelic TP53 inactivation; and
         3.           excludes:
                 1.             leukaemia including acute myeloid leukaemia;
                 2.          myeloproliferative neoplasms including chronic myeloid leukaemia, chronic neutrophilic leukaemia, chronic eosinophilic leukaemia, polycythaemia vera, essential thromobocythaemia, primary myelofibrosis, and juvenile myelomonocytic leukaemia;
                 3.        aplastic anaemia; and
                 4.         Myelodysplastic/myeloproliferative neoplasms in the overlap category, including myelodysplastic/myeloproliferative neoplasm with neutrophilia; and myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis; and myelodysplastic/myeloproliferative neoplasm not otherwise specified.
Note: Myelodysplastic neoplasms are also called myelodysplastic syndromes and myelodysplastic disorders
 1.           While myelodysplastic neoplasm (syndrome) attracts ICD‑10‑AM codes